Note: This Guidance is no longer in effect and is for historical purposes only.
Related Materials: Anti-SARS-CoV-2 Monoclonal Antibody Treatment Information for Providers and Facilities (Q&A) | Bamlanivimab Distribution Fact Sheet | Bamlanivimab plus Etesevimab Distribution Fact Sheet | Casirivimab and Imdevimab Distribution Fact Sheet | More Healthcare & Testing Guidance | All Guidance | More Languages
The currently available anti-SARS-CoV-2 monoclonal antibodies that have received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) include:
All three products cover current variants circulating in California.
Given high demand and limited supply, the U.S. Department of Health and Human Services (HHS) announced that effective September 13, 2021, distribution of all anti-SARS-CoV-2 monoclonal antibody products will transition to a state/territory-coordinated distribution system. This means that facilities cannot directly order these products. At this time, there is no timeline for when direct ordering will be available.
Weekly distribution amounts of each anti-SARS-COV-2 monoclonal antibody product for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted to the federal government.
CDPH will allocate product to local jurisdictions. Once the number of doses has been allocated, each jurisdiction's Medical and Health Operational Area Coordinator (MHOAC) will assist in determining which facilities within the jurisdiction receive product. Facilities that require anti-SARS-COV-2 monoclonal antibody products should contact their MHOACs to discuss available supply in their jurisdiction.
SARS-COV-2 monoclonal antibody products should
contact their MHOACs to discuss available supply in their jurisdiction.
Originally published on January 4, 2021